Hepcidin as an emerging predictor biomarker of leptomeningeal metastases in patients with metastatic breast cancer
Abstract Background Leptomeningeal metastatic disease (LMD) occurs in 5–19% of solid tumor cases, with breast cancer being a leading cause. Limited penetration of therapeutic agents into the CNS and increased patient survival may contribute to the rising incidence. Diagnosis relies on cerebrospinal...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMC
2025-11-01
|
| Colección: | BMC Cancer |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s12885-025-15124-6 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|